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Abstract
Background: Increasing evidence indicates that closed vitrification has been successfully used in the
cryopreservation of human oocytes and embryos. Little information is available regarding the neonatal outcome of
closed blastocysts vitrification. The aim of this study was to evaluate the effectiveness and safety of blastocyst
vitrification using a high-security closed vitrification system compared with an open vitrification system.
Methods: A total of 332 vitrified-warmed blastocyst transfer cycles between April 2010 and May 2012 were
analyzed retrospectively. The post-thaw survival rate, implantation rate, clinical pregnancy rate, live birth rate, and
neonatal outcome were recorded.
Results: There were no significant differences between the open vitrification group and the close vitrification group
regarding the post-thaw survival rate (98% versus 95.8%), clinical pregnancy rate (47.6% versus 42.2%), implantation
rate (42.9% versus 35.6%), and live birth rate (39.8% versus 32.1%). In total, 332 warming cycles produced 131
healthy babies. There were no significant differences in the mean gestational age, the birth weight, and the birth
length between the two groups. No adverse neonatal outcomes were observed in the children born after the
transfer of closed vitrified blastocysts compared with the transfer of open vitrified blastocysts.
Conclusions: These data suggest that blastocyst vitrification using a closed vitrification device seems safe and
effective with results comparable to those obtained through open vitrification.
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Background
Vitrification has been widely used for oocyte and embryo
cryopreservation in assisted reproduction clinics. Better
post-thawing survival rates of vitrification compared with
the rates of slow-freezing of blastocysts have been demon-
strated [1]. Blastocyst vitrification using open carrier, such
as a cryoloop, yields comparable clinical outcomes and con-
genital defect rates as fresh blastocyst transfer [2]. Since an
open vitrification system has a theoretically higher risk of
microbiological transmission through liquid nitrogen [3-5],
there is a movement towards the use of closed vitrification
carriers. One concern with a closed vitrification system is
whether the lower cooling rate would have an adverse
effect on vitrification. The cooling rate with the open
carriers has been reported to be superior to −20,000°C/
min [6,7], whereas the cooling rate with close carrier is
below −2000°C/min [8].
A growing body of evidence indicates that closed vitrifica-
tion using the CBS High Security straw has been success-
fully used in the cryopreservation of human blastocysts
from the early cavitation stage to the expanded blastocyst
stage or derived from biopsied embryos [9,10]. The DNA
damage in the blastomeres was comparable in mice
embryos vitrified on the open Cryoloop and the closed
CBS High Security straw [11]. Little information is available
concerning the perinatal outcome of closed blastocysts
vitrification. The aim of the present study is to evaluate the
clinical efficiency and safety of blastocyst vitrification using
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a closed device (CBS High Security straws; Cryo Bio System)
compared with open device (Cryoleaf).
Methods
Study design
The study was approved by the Ethics Committee of the
Peking University Third Hospital. A total of 332 blastocysts
warming cycles of IVF/ICSI patients performed between
April 2010 and May 2012 were analyzed retrospectively.
The patients were <40 years old with a BMI (body mass
index) <30 kg/m2, without previous viral infection (hepatitis
B-C, HIV and syphilis). All the patients used long or short
protocols for ovarian hyperstimulation. Thirty-six hours
after the hCG administration, the oocytes were retrieved
and fertilized using conventional IVF or ICSI. Normal
fertilization was assessed by the presence of two pronuclei
and a second polar body at 16–18 hours after insemin-
ation. The zygotes were cultured in cleavage medium
(Vitrolife, Sweden) to day 3 and the transfer. The blastocyst
vitrification was performed for the patients with the culture
of surplus embryos to the blastocyst stage after the fresh
day 3 embryo transfer. Only expanded or hatching blasto-
cysts (according to Gardner’s grading system [12]) with ICM
(Inner Cell Mass) and trophoetoderm type above grade CC
were selected for cryopreservation on day 5 or day 6.
Vitrification of blastocysts
Prior to the vitrification, the expanded or hatching
blastocysts were treated with a laser pulse for the artificial
shrinkage of the blastocoelic cavity. The vitrification
and warming procedures were similar to those reported
by Mukaida T et al. [13]. The solutions were incubated
at 37°C for 30 min prior to the vitrification process, and
all the steps were conducted at 37°C. The blastocyst was
first incubated for 1 min in a droplet of basal medium.
The basal medium was Quinns Advantage medium with
HEPES (SAGE, Trumbull, CT, USA) supplemented with
20% (v/v) Human Serum Albumin (HSA, Vitrolife, Sweden).
The blastocyst was moved to a droplet of equilibration
solution composed of 7.5% (v/v) DMSO (Sigma Chemical
Co., MO, USA) and 7.5% (v/v) ethylene glycol (Sigma
Chemical Co., MO, USA) in basal medium for 2 min.
The blastocyst was then transferred into a droplet with
vitrification solution containing 15% (v/v) DMSO, 15%
(v/v) ethylene glycol and 0.65 mol/L sucrose in a basal
medium for 30 s and immediately placed in the McGill
Cryoleaf (ORIGIO, Malov, Denmark.) and plunged into
liquid nitrogen. As for the closed vitrification, the protocol
was similar to that of the open vitrification except for
loading the blastocyst onto the closed CBS High Security
straws (Cryo BioSystem, Paris, France). The straw was
heat sealed and plunged into liquid nitrogen as described
previously [9]. The vitrification procedures carried out did
not exceed 90 s.
Warming and recovery of blastocysts
The blastocysts were unloaded from the carrier into
warming solution 1 containing 0.33 M of sucrose (Sigma
Chemical Co., MO, USA) in a basal medium with 20%
HSA. After 2 minutes they were transferred into warm-
ing solution 2 containing 0.2 M of sucrose for 3 minutes.
Finally, the blastocysts were washed in a droplet of washing
solution (HEPES-buffered medium supplemented with
20% HSA) for 5 min. All the warming steps were per-
formed at 37°C. The blastocysts were unloaded from the
different carriers as follows: (1) Cryoleaf: the blastocysts
were recovered by quickly immersing the sheet in warming
solution 1. (2) CBS High Security Straw: the straw was held
in liquid nitrogen, and the upper end of the outer straw
was cut using wire cutters. The inner straw with a gutter
was quickly pulled out of the sheath and immersed in
warming solution 1 to unload the embryos. After warming,
the blastocysts were transferred to a culture dish with
blastocyst medium (G-2, Vitrolife, Sweden) to assess their
morphological survival and perform assisted hatching
using a laser. The blastocysts with good survival (less than
half of the blastocysts showing signs of damage) and the
re-expanded blastocysts were transferred 2 h after the
in vitro culture. The blastocysts with less than 50% damage
but showing no signs of expansion were further cultured
for an additional period of 24 h. The transfer will be
cancelled if no signs of re-expansion were present.
Thawed blastocyst transfer
The thawed blastocyst transfer was performed in natural
monitored cycles or in programmed artificial cycles. For
the natural monitored cycles, the thawed blastocyst transfer
was scheduled for 5 days after ovulation. Luteal support
was provided with intramuscular injections of progesterone
20–40 mg from the night of transfer. For the hormone
replacement therapy, endometrial development was
achieved by daily oral estradiol administration. When the
endometrial thickness was suitable, this phase was comple-
mented by the administration of progesterone. The blasto-
cyst transfers were performed on day 5 after the initiation
of the progesterone treatment. The serum HCG levels were
measured 12 days after the transfer.
Outcome parameters
All of the pregnant women were followed until two months
after parturition, and the details of the clinical outcome
were obtained from the medical records of our clinic. The
blastocyst survival was defined as less than one-half of the
blastocysts showing signs of damage. Clinical pregnancy
was defined as the presence of gestational sacs observed
on an ultrasound scan at least 5 weeks after the embryo
transfer. The implantation rate (the number of gestational
sacs divided by the number of transferred embryos), the
miscarriage rate per clinical pregnancy and the live birth
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rate per transfer were measured. The neonatal outcomes
evaluated were the mean gestational age, gender, pre-
term birth rate, birth weight, birth length and major
and minor anomalies. Low birthweight was defined as
birth weight <2500 g. high birthweight was defined as
birth weight ≥4000 g. Preterm birth was defined as birth
before 37 weeks of gestation. Postterm birth was defined
as birth after 42 weeks of gestation.
Statistics
The data were analyzed by the Chi-square test or Student’s
t-test. The P-values <0.05 were regarded as significant.
Results
A total of 226 and 106 vitrified-warmed blastocyst transfer
cycles were performed for the closed vitrification group
and the open vitrification group, respectively. There were
no significant differences in maternal age at the time of
transfer, BMI, reason for infertility, method of fertilization
and average number of transferred embryos between the
two groups (P > 0.05, Table 1). Blastocyst survival rate was
98.0% in the open vitrification group and 95.8% in the
closed vitrification group. The clinical pregnancy, implant-
ation, miscarriage and live birth rates were similar between
the two groups (P > 0.05, Table 2). Three cases of transfers
in the closed vitrification group took place 24 hours later,
but only one woman became pregnant. The pregnancy
complications and spontaneous vaginal delivery rates were
comparable between the two groups.
A total of 132 babies (70 males and 62 females) were
born from 111 deliveries as the result of vitrified-warmed
blastocyst transfers. There were no significant differences
in gender rate and multiple-birth rate (P > 0.05, Table 3).
Among the 90 delivered singletons, 30 were derived
from the open vitrification group and 60 from the closed
vitrification group. Of the 21 women who gave birth to
twins after the transfer of two vitrified-warmed blastocysts,
11 were from the open vitrification group and 10 were from
the closed vitrification group. For the singleton and twin
groups, there were no significant differences in the
mean gestational age, the mean birthweight, the mean birth
length, the low birthweight rate, and the preterm birth rate
between the two vitrification groups (P > 0.05, Table 4).
Four babies (three following twin pregnancies) of low
birthweight were from the open vitrification group, whereas
nine babies (four following twin pregnancies) of low
birthweight were from the closed vitrification group.






(106 cycles) (226 cycles)
Patient age at transfer (years) 33.1 ± 4.4 32.5 ± 4.1 0.171
BMI (kg/m2) 23.38 ± 3.3 24.19 ± 4.6 0.105
No. of primary infertility 68 (64.2) 139 (61.5) 0.643
Reason for infertility
Female factor 59 (55.7) 114 (50.4) 0.375
Male factor 18 (17.0) 46 (20.4) 0.468
Others 29 (27.4) 66 (29.2) 0.729
Method of fertilization
IVF 64/106 (60.4) 136/226 (60.2) 0.972
ICSI 40/106 (37.7) 86/226 (38.1) 0.956
Half ICSI 2/106 (1.9) 4/226 (1.7) 0.941
Mean number of embryos
transferred
1.39 ± 0.52 1.31 ± 0.53 0.193
Values are mean ± SD or n/total (%).






(106 cycles) (226 cycles)
Cryosurvival rate 147/150 (98.0) 295/308 (95.8) 0.224
Cancellation rate 3/106 (2.8) 8/226 (3.5) 0.736
Clinical pregnancy rate/transfer 49/103 (47.6) 92/218 (42.2) 0.365
Implantation rate/transferred
blastocysts
63/147 (42.9) 105/295 (35.6) 0.138
Pregnancy loss
Miscarriage rate/pregnancy 8/49 (16.3) 21/92 (22.8) 0.363
Ectopic rate/pregnancy 0 1/92 (1.1) 1.000
Live birth rate/transfer 41/103 (39.8) 70/218 (32.1) 0.176
Complications during
pregnancies
Gestational diabetes 1/103 (0.97) 3/218 (1.3) 0.760
Hypertension 1/103 (0.97) 2/218 (0.92) 0.963
Placenta previa 0 1/218 (0.4) 1.000
Mode of delivery
Spontaneous vaginal delivery 5/41 (12.2) 10/70 (14.3) 0.756
Cesarean section 36/41 (87.8) 60/70 (85.7) 0.756
Values are n or n/total (%).









52/147 (35.4) 80/295 (27.1) 0.074
Male rate 29/52 (55.8) 41/80 (51.3) 0.611
Female rate 23/52 (44.2) 39/80 (48.7) 0.611
Multiple birth rate 11/41 (26.8) 10/70 (14.3) 0.103
Singletons 30 60
Twins 11 10
Stillbirth rate /transfer 1/103 (0.97) 0 0.321
Values are n or n/total (%).
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No significant differences in the rate of post-term birth
and high birthweight between singletons in the closed
vitrification group and singletons in the open vitrification
group. A total of 332 warming cycles produced 131 healthy
babies. No birth defects occurred among the newborns,
except one baby of twins died from fetal distress in the
open vitrification group.
Discussion
These findings demonstrate that a closed human blastocyst
vitrification system with artificial shrinkage could be an
effective and safe procedure for vitrification.
There have been concerns with the closed system
because the slower cooling rate might cause ice crystal
formation that could potentially be detrimental to survival.
In this study, the closed vitrification protocol, such as the
concentration of the cryoprotectants, the temperatures
and the exposure times were identical to those described
with the open vitrification device. This finding demon-
strates that, although a lower cooling rate is a consequence
of using a closed vitrification device, it did not affect the
vitrification outcome negatively, which might be because
of the dominance of the warming rate over the cooling
rate in the process of vitrification [14]. In agreement
with our data, a recent prospective randomized study
that included 432 warming cycles demonstrated that closed
or open vitrification with the VitriSafe device rendered
comparable clinical results [15]. Although there are no
significant differences, most likely because of the small
sample size, the indexes of the clinical outcome of open
vitrification were most likely better than those of closed
vitrification. In this regard, further study is warranted.
Another concern with vitrification is that the risk of
detrimental intracellular ice formation is higher in the ex-
panded blastocysts compared with the early blastocysts
because of the large fluid-filled cavity. Artificial shrinkage
or collapse of the expanded blastocysts by mechanical
methods or laser prior to vitrification, as suggested in our
study, has been shown to improve survival and increase
the clinical pregnancy rates [16]. One published group
indicates that the survival rate of full and expanded
blastocysts in a closed vitrification system without artificial
shrinkage, which was replaced by extended exposure time
to the cryoprotectants, is acceptable [9].
Although pregnancies after the transfer of thawed frozen
embryos appear to have better obstetric and perinatal out-
comes than those after fresh embryos [17,18], the perinatal
outcome of vitrified cleavage embryos using the Cryoleaf
carrier system yields comparable outcomes with those of
the fresh cycles. No significant differences were observed
in the mean gestational age, birth weight, sex ratio, con-
genital birth defects, and abnormalities [19]. The health of
children born after blastocyst vitrification has always been
of concern. Most studies of blastocyst vitrification are
small cases without data on the neonatal outcomes.
Wikland M. et al. demonstrated that children born after the
transfer of open vitrified blastocysts (using the cryoloop),
compared with fresh blastocysts, yields similar neonatal
outcomes [20]. The largest study on vitrified blastocysts
that included 147 children showed no differences in
the obstetric outcomes for children born after open
vitrified blastocysts (using the cryoloop) compared with
the children born after fresh blastocysts; however, a
low birthweight rate of 43.5% among all the children in
the vitrified group was reported [2]. There are very few
studies on the follow-up of children after transfer of
closed vitrified blastocysts. Wirleitner et al. showed
that the length of the storage time of vitrified blasto-
cysts in closed devices that were stored for 6 years in
liquid nitrogen had no detected negative effect on the
health of the children [21]. In this study, 332 warming
cycles produced 131 healthy babies. No adverse outcome
was observed in the children born after the transfer of
closed vitrified blastocysts compared with the children
born after the transfer of open vitrified blastocysts in
terms of birth weight, birth length or birth defects. In
this regard, it is suggested that closed vitrification has
an advantage for the cryopreservation of blastocysts
derived from patients with viral infections, such as
hepatitis B-C and HIV.











Gestational age (wks) 38.3 ± 1.3 37.9 ± 1.5 0.175 37.2 ± 1.4 37.4 ± 1.5 0.844
GA < 37 weeks 2/30 (6.7) 9/60 (15.0) 0.426 4/11 (36.4) 4/10 (40) 1.000
GA ≥ 42 weeks 1/30 (3.3) 2/60 (3.3) 1.000 0 0
Birth weight (g) 3248 ± 408 3163 ± 481 0.410 2800 ± 380 2598 ± 364 0.091
<2500 g 1/30 (3.3) 5/60 (8.3) 0.654 3/11 (27.3) 4/10 (40) 0.659
≥4000 g 3/30 (10.0) 7/60 (11.7) 0.813 0 0
Birth length (cm) 49.7 ± 1.6 50.4 ± 1.3 0.086 48.8 ± 1.6 48.9 ± 1.7 0.858
Values are mean ± SD or n/total (%).
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Conclusions
One limitation of this study is its limited size; however,
the results are promising. The data suggest that closed
blastocyst vitrification seems a safe alternative for open
blastocyst vitrification without affecting the efficiency of
cryopreservation. Long-term child follow-up studies are
needed to investigate open and closed vitrification systems.
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